TABLE II.

Total Prevalence of Bladder Exstrophy in 22 Surveillance Programs of the International Clearinghouse for Birth Defects Surveillance and Research (ICBDSR)

Surveillance program	Period	Births	Total number of cases	% of total cases that were ETOPFA	Prevalence per 100,000 births	95% CI
Canada Alberta	1980–2005	1,062,483	26	0	2.45	1.60–3.59
USA Utah	1997–2004	380,706	4	0	1.05	0.29–2.69
USA Atlanta	1968–2004	1,283,999	24	0	1.87	1.20–2.78
USA Texas	1996–2002	2,054,788	33	0	1.61	1.11–2.26
Mexico RYVEMCE	1978–2005	1,058,885	34	NP	3.21	2.22–4.49
South America ECLAMC	1982–2006	4,556,173	35	NP	0.77	0.54–1.07
Finland	1993–2004	713,494	33	6.1	4.63	3.18–6.50
Wales	1998–2004	222,309	6	0	2.70	0.99–5.87
Northern Netherlands	1981–2003	369,658	11	0	2.98	1.49–5.32
Germany Saxony–Anhalt	1980–2004	355,184	9	33.3	2.53	1.16–4.81
Slovak Republic	2000–2005	318,257	4	0	1.26	0.34–3.22
Hungary	1980–2005	3,022,194	75	0	2.48	1.95–3.11
France Central East	1979–2004	2,500,214	58	20.7	2.32	1.76–3.00
Italy North East	1981–2004	1,186,497	28	3.6	2.36	1.57–3.41
Italy Emilia Romagna	1982–2004	558,176	18	0	3.22	1.91–5.10
Italy Tuscany	1992–2004	336,744	11	18.2	3.27	1.63–5.84
Italy Campania	1992–2004	643,962	10	0	1.55	0.74–2.86
Italy Sicily	1991–2002	216,257	7	0	3.24	1.30–6.67
Spain ECEMC	1980–2004	2,045,751	52	NR	2.54	1.90–3.33
Israel	1975–2005	151,562	7	14.3	4.62	1.86–9.52
China Beijing	1992–2005	1,927,622	10	NR	0.52	0.25–0.95
Australia Victoria	1983–2004	1,390,179	51	3.9	3.67	2.73–4.82
Total		26,355,094	546	4.2a	2.07	1.90–2.25

ECEMC, Estudio Colaborativo Español de Malformaciones Congénitas; ECLAMC, Estudio Colaborativo Latino Americano de Malformaciones Congénitas; RYVEMCE, Registro y Vigilancia Epidemiológica de Malformaciones Congénitas; ETOPFA, elective termination of pregnancy for fetal anomaly; CI, confidence interval; NP, not permitted; NR, not reported.

^aThe percentage computed on the 18 surveillance programs registering ETOPFA is 5.5% (n = 23/415).